Urologic cancer in Thailand

Lojanapiwat, Bannakij

doi:10.1093/jjco/hyv125

Cited by 20 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, chemotherapy might not provide survival benefits for CRPC patients and may have an unacceptably high level of toxicity . Therefore, finding effective non‐toxic compounds that can inhibit cancer metastasis for use in clinical trials to improve survival rates among prostate cancer patients is urgently required …”

Section: Introductionmentioning

confidence: 99%

“…3 Therefore, finding effective non-toxic compounds that can inhibit cancer metastasis for use in clinical trials to improve survival rates among prostate cancer patients is urgently required. 4 Curcumin has been used as a food additive and in traditional medicine in many Asian countries. It has a wide range of biological activities, such as anti-inflammatory, anti-oxidative, anti-metastatic, as well as multi-drug resistance reversing properties.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

et al. 2018

View full text Add to dashboard Cite

Many prostate cancer patients develop resistance to treatment called castration‐resistant prostate cancer (CRPC) which is the major cause of recurrence and death. In the present study, four cyclohexanone curcumin analogs were synthesized. Additionally, their anticancer progression activity on CRPC cell lines, PC3 and PLS10 cells, was examined. We first determined their anti‐metastasis properties and found that 2,6‐bis‐(4‐hydroxy‐3‐methoxy‐benzylidene)‐cyclohexanone (2A) and 2,6‐bis‐(3,4‐dihydroxy‐benzylidene)‐cyclohexanone (2F) showed higher anti‐invasion properties against CRPC cells than curcumin. Analog 2A inhibited both MMP‐2 and MMP‐9 secretions and activities, whereas analog 2F reduced only MMP activities. These findings suggest that the compounds may inhibit CRPC cell metastasis by decreased extracellular matrix degradation. Analog 2A, the most potent analog, was then subjected to an in vivo study. Similar to curcumin, analog 2A was detectable in the serum of mice at 30 and 60 minutes after i.p. injections. Analog 2A and curcumin (30 mg/kg bodyweight) showed a similar ability to reduce tumor area in lungs of mice that were i.v. injected with PLS10 cells. Additionally, analog 2A showed superior growth inhibitory effect on PLS10 cells than that of curcumin both in vitro and in vivo. The compound inhibited PLS10 cells growth by induction of G1 phase arrest and apoptosis in vitro. Interestingly, analog 2A significantly decreased tumor growth with downregulation of cell proliferation and angiogenesis in PLS10‐bearing mice. Taken together, we could summarize that analog 2A showed promising activities in inhibiting CRPC progression both in vitro and in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The global composition of urologic cancer patients has been continuously evolving due to multiple forces [3,2,1,[4][5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

The relationship between urologic cancer outcomes and national Human Development Index: trend from 2012 to 2018

Zhang¹,

H²,

Jiang³

et al. 2019

Preprint

View full text Add to dashboard Cite

Objectives To describe the influence of the socioeconomic development on worldwide age-standardized incidence and mortality rates, as well as mortality-to-incidence ratio (MIR) and 5-year net survival of urologic cancer patients from 2012 to 2018. Methods The HDI values were obtained from the United Nations Development Programme, data on age-standardized incidence/mortality rates of prostate, bladder and kidney cancer were retrieved from the GLOBOCAN database, 5-year net survival was provided by the CONCORD-3 program. We then evaluated the association between incidence/MIR/survival and HDI, with a focus on geographic variability as well as temporal patterns during the last 6 years. Results Urologic cancer incidence rates were positively correlated with HDIs, and MIRs were negatively correlated with HDIs. Prostate cancer survival also correlated positively with HDIs, solidly confirming the interrelation among cancer indicators and socioeconomic factors. Most countries experienced incidence decline over the most recent 6 years, and a substantial reduction in MIR was observed. Survival rates of prostate cancer have simultaneously improved. Conclusion Development has a prominent influence on urologic cancer outcomes. HDI values are significantly correlated with cancer incidence, MIR and survival rates. HDI values have risen along with increased incidence and improved outcomes of urologic caner in recent years.

show abstract

“…The incidence in Thailand is 7.2/100,000 of population and the mortality is 3.7/100,000 1 . In Thailand, patients usually present with advanced stage PC when compared with the USA and Europe 2 .…”

Section: Introductionmentioning

confidence: 99%

Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer

Kongseang

Attawettayanon

Kanchanawanichkul

et al. 2017

Prostate International

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to identify the predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (PC) with or without distant metastasis.MethodsA retrospective review of PC patients was conducted of the medical records. We enrolled 246 patients who received primary ADT. PC patients treated with ADT for presumed nonlocalized PC were evaluated on the efficacy of ADT using prostate-specific antigen (PSA) time to progression (TTP) and compared factors associated with TTP in patients with distant metastasis and patients without distant metastasis.ResultsA total of 246 patients were treated primarily with ADT. The median follow-up period was 20.2 months. One hundred and ninety-one patients had metastatic disease. The median TTP on ADT for the distant metastasis group was 14.8 months versus 60.1 months in the without distant metastasis group (P < 0.0001). In the univariate analysis only, PSA nadir after ADT was associated with longer TTP (hazard ratio, 10.69; 95% confidence interval, 5.56–20.57). In the multivariate analysis, high grade tumor and PSA nadir were independent factors associated with a shorter TTP.ConclusionIn this study of hormone-sensitive PC patients treated with ADT for nonlocalized PC, high grade tumor and PSA nadir were predicting factors of this treatment.

show abstract

Urologic cancer in Thailand

Cited by 20 publications

References 20 publications

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

The relationship between urologic cancer outcomes and national Human Development Index: trend from 2012 to 2018

Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer

Contact Info

Product

Resources

About